Study with oral semaglutide in T2D meets primary endpoint
29/10/2024
The SOUL trial demonstrates a 14% reduction in the risk of MACE with oral semaglutide versus placebo on top of standard of care in patients with T2D and established CVD and/or CKD.
The SOUL trial demonstrates a statistically significant 14% reduction in the risk of MACE with oral semaglutide versus placebo on top of standard of care in patients with T2D and established CVD and/or CKD. The safety profile of oral semaglutide was comparable to previous oral semaglutide trials.
The phase 3, double-blinded, randomized CV outcomes trial enrolled 9,650 patients with T2D and established CVD and/or CKD. 49% of patients used SGLT2i at some point during the trial as part of standard of care. The primary endpoint was the first occurrence of MACE defined as CV death, non-fatal MI or non-fatal stroke.
Results from the SOUL trial will be presented at a scientific conference in 2025.